neostigmine has been researched along with Weight Loss in 1 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
Weight Loss: Decrease in existing BODY WEIGHT.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karanth, S | 1 |
| Liu, J | 1 |
| Ray, A | 1 |
| Pope, C | 1 |
1 other study available for neostigmine and Weight Loss
| Article | Year |
|---|---|
Comparative in vivo effects of parathion on striatal acetylcholine accumulation in adult and aged rats.
Topics: Acetylcholine; Aging; Animals; Binding, Competitive; Cholinesterase Inhibitors; Corpus Striatum; Def | 2007 |